Harbour BioMed Signs Out-License Agreement with AstraZeneca for HBM7022 to Treat Solid Tumors Using HBICE Platform
Shots:
- HBM to receive $25M up front & is eligible to receive an additional fee of ~$325M upon the achievement of development, regulatory & commercial milestones along with royalties on net sales
- AstraZeneca to get an exclusive license globally for the research, development, registration, manufacturing & commercialization of HBM7022 (CLDN18.2xCD3 bispecific Ab) & will be solely responsible for all costs and activities
- HBM7022 is currently being studied in the pre-clinical stage that crosslinks tumor & T cells by targeting a tumor-associated Ag (Claudin18.2) and CD3 that leads to potent T cell activation and tumor elimination
Ref: PR Newswire | Image: Businesswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
